about
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivoPredictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [CorrectedQuantitative amyloid imaging using image-derived arterial input functionQuantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study GroupClinical amyloid imaging in Alzheimer's disease.Amyloid imaging in dementias with atypical presentation.Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.Ligand-based molecular MRI: O-17 JJVCPE amyloid imaging in transgenic mice.Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections.In vivo amyloid imaging in Alzheimer's disease.Amyloid imaging: from benchtop to bedside.Amyloid imaging using fluorine-19 magnetic resonance imaging ((19)F-MRI).Preclinical characterization of amyloid imaging probes with multiphoton microscopy.Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agentsIn vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementiaCommunicating mild cognitive impairment diagnoses with and without amyloid imaging.Amyloid imaging in mild cognitive impairment subtypes.Amyloid imaging using high-field magnetic resonance.In vivo human amyloid imaging.Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept.Feasibility of amylin imaging in pancreatic islets with β-amyloid imaging probes.Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.Transcriptome-guided amyloid imaging genetic analysis via a novel structured sparse learning algorithmWhole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions.Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.Should we disclose amyloid imaging results to cognitively normal individuals?Amyloid imaging of Lewy body-associated disordersSparse Clustering with Resampling for Subject Classification in PET Amyloid Imaging Studies.Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects.AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's diseaseThe use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience.Amyloid imaging and memory change for prediction of cognitive impairment.PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's diseaseDevelopment of a process to disclose amyloid imaging results to cognitively normal older adult research participantsAmyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.Amyloid imaging for dementia in clinical practice.Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.
P921
Q24648007-5285AC58-E714-4295-A179-502F10C21439Q27007436-FE706D38-0EDB-482A-B393-9624A678DB95Q28545789-2242AC8D-088F-48E3-8447-203DF923C4E7Q28550984-84A44E20-1663-4523-8CA8-856D9E00EFAFQ29397707-DA4B7E3D-EA82-461B-881F-AC68C4C143FFQ30417342-90DAC31C-A451-4F5E-9CC2-4F450A35DEE1Q30422060-93CEB38E-0EBB-4412-A2C5-54D7ACAE5CF5Q30867528-25704B19-2578-416F-B162-1F40834C6DB7Q30872658-ACC1C483-3141-4A40-A7CA-B0B152C0A42DQ30889969-D97D6A1B-FB49-4714-9864-BD79F18DAC14Q31024441-320EBF18-0B8C-4A49-9874-E600F8C1BF4CQ31037122-397D4A84-6811-4F09-A0BB-D358F7BB299CQ31055018-C0971E2A-FE40-4BA8-9031-89E9AC9237D7Q33385904-98228374-EF51-47DD-ADB9-A83EEF292FCCQ33601277-86B00371-A82F-4375-A3C3-A0C26F471F2FQ33640373-95642629-5D9F-4A6B-ADFF-3917F2C53893Q33689424-87284C3A-8271-4F80-AAB0-4B018978869FQ33706905-A98E73D0-FC8E-480B-8AB9-3D9948D192ABQ33790277-09617C7A-18EF-4411-82B4-C156FF9D680BQ33856185-B3DD498E-A254-4691-8115-7559CE2496F6Q34004313-995E346E-8187-4212-A3BD-42A0F030E42DQ34072780-72FC19C3-52A7-430B-B139-33442E5E962DQ34102715-5317304C-8168-4F55-A3D6-11B8E8C12E12Q34103206-83607FEE-68E7-4D24-917A-8B8087578EA7Q34113947-E93DF089-0CFC-4B33-AAF5-F0C24854D8D6Q34207044-600A7052-D590-4A01-9224-734326BAC4B0Q34214255-BACDE5B2-00DA-483A-AC7E-FCB5CFF6A206Q34286140-B82D1AF2-AB2E-4B0F-8F12-A80D3DB512A3Q34300244-D154DC23-A185-4174-B914-777579687E08Q34404323-B6A747B9-3B16-4EAE-98D9-2E84122321D8Q34434351-F952A916-54FB-49DD-A2E6-64E766CC3E26Q34541038-79EDAF7F-B0EA-4678-B137-B6EAB0C22B95Q34589414-C244D9C0-FC36-45DA-8750-4387FDCC0360Q35008214-952F68EF-27FC-4BB7-947E-D581965A3748Q35029095-25CDF0FF-EB0D-4CF8-8F51-AEAF5F13B44BQ35579225-7888B77A-C18F-4E33-95B2-C11BEBEAA8CDQ35595661-791A64A9-C0E8-4DDA-8A13-F843A2DCC91DQ35600979-D51EF860-0108-464A-8E54-42536A090D54Q35690134-B5D6F35A-77E6-45B0-A8C8-6BA823CA1988Q35692953-838F115D-FC53-4955-B009-E5C7B31D9FEF
P921
description
set of techniques aimed at imaging amyloid plaques
@en
name
amyloid imaging
@en
type
label
amyloid imaging
@en
prefLabel
amyloid imaging
@en